Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why acquisitions boost its outlook.

Earlier in February, Hims & Hers Health rallied as it was set to debut its controversial Super Bowl ad, where it positioned itself as the “affordable, doctor-trusted, formulated in the US ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) plummeted following its fourth-quarter earnings report. The stock had ...

Highlights,Several financial firms, including Keybank National Association OH, have acquired new stakes in Hims & Hers Health.,Institutional market participation continues to shape financial activity ...

It should be noted that Hims and Hers stock had jumped 43% in the week prior to the announcement, which has been attributed to the acquisition of Tybre Labs and a controversial Super Bowl ad.

Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients. Compounded GLP-1s are custom-made by compounding ...

Investors became excited about the prospects of the company, while its Super Bowl ad and the acquisition ... Drug Administration's shortage list. Hims & Hers has been selling semaglutide-based ...